Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
A pair of independent analyses of patient-level data commissioned by a Yale University open data program show that Medtronic's Infuse bone-growth putty is equivalent to bone grafts, with 1 concluding that early Infuse research was biased.
Study results revealed in Europe this week cast doubt on the efficacy of renal denervation for treating high blood pressure.
The effectiveness of renal denervation in treating high blood pressure could be much less than observed in clinical trials, according to a Belgian study of ambulatory blood-pressure monitoring in patients with resistant hypertension treated using renal denervation instead of drugs.
European regulators gave Medtronic the green light for a 1st-of-its-kind spinal ReDux Plier orthopedic surgical instrument.
Medtronic successfully fends off 1 of the 3 ongoing German patent infringement battles brought by Edwards Lifesciences over transcatheter aortic valve implantation technology.
A federal judge raises the royalty rate NuVasive must pay Medtronic on sales of some of its spinal implants, but not as high as Medtronic wanted.
Everest Metal Orthopedics founder Chris Huntington steps down from his position as COO at Symmetry Medical after 7 years at the orthopedics company following its merger with Everest.
Symmetry Medical (NYSE:SMA) said its chief operating officer Chris Huntington has left the company. Huntington founded Everest Metal Orthopedics and joined Symmetry amid a 2006 merger. He was promoted within Symmetry from his initial position as VP of business development.